U.S. markets closed

OPKO Health, Inc. (OPK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.0200+0.1200 (+3.08%)
At close: 04:00PM EST
4.0200 0.00 (0.00%)
After hours: 07:59PM EST

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100

IndustryDiagnostics & Research
Full Time Employees5,269

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip Frost Ph.D.Chairman & CEO971.2kN/A1936
Dr. Jane H. Hsiao Ph.D., MBAVice Chairman & Chief Technical Officer911.2kN/A1947
Mr. Adam E. LogalSr. VP & CFO1.11MN/A1978
Mr. Steven D. RubinExec. VP of Admin. & Director821.2kN/A1960
Dr. Jon R. CohenSr. VP & Director1.74MN/A1955
Dr. Arie GutmanPres of APIN/AN/A1954
Mr. James DeMarcoSr. VP of Pharmaceutical SalesN/AN/AN/A
Dr. Akhtar AshfaqSr. VP of Clinical R&D and Medical AffairsN/AN/AN/A
Ms. Jane Pine Wood Esq., J.D.Chief Legal Officer of Bio-Reference LaboratoriesN/AN/A1962
Dr. David Okrongly Ph.D.Pres of OPKO DiagnosticsN/AN/A1959
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Corporate Governance

OPKO Health, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.